Preliminary dosimetry assessments revealed that [161Tb]Tb-PSMA had a slightly higher absorbed doses to organs at risk than [177Lu]Lu-PSMA RLT but notably higher doses to tumor lesions, suggesting a potentially superior therapeutic index [63]. The gene discussed is FOLH1; the disease is neoplasm.